Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: A pilot study

Transplant International

Volumn 23, Issue 1, 2010, Pages 31-37

  Ross, Heather ^a   Pflugfelder, Peter ^b   Haddad, Haissam ^c   Cantarovich, Marcelo ^d   White, Michael ^e   Ignaszewski, Andrew ^f   Howlett, Jonathan ^g   Vaillancourt, Marc ^h   Dorent, Richard ^i,k   Burton, Jeffrey R ^j  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MONTREAL HEART INSTITUTE   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h Novartis Pharmaceuticals Canada Inc   (Canada)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF ALBERTA   (Canada)

^k HÔPITAL TENON   (France)

more..

Author keywords

CsA; Cyclosporine; Dose reduction; Everolimus; Heart transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRIACYLGLYCEROL;

ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; APHTHOUS ULCER; ARTICLE; BRONCHITIS; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEADACHE; HEART GRAFT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LINGUAL EDEMA; LIVER; MALE; MEDIASTINITIS; MULTICENTER STUDY; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RASH; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTE COUNT; TONGUE EDEMA; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; SIROLIMUS;

EID: 70949103639     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00940.x     Document Type: Article

References (25)

1. Valantine H. Cardiac allograft vasculopathy after heart transplantation: Risk factors and management. J Heart Lung Transplant 2004 23 (Suppl. 5 S187.
2. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006 6 : 1248.
3. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997 64 : 36.
4. Bohler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998 30 : 2195.
5. Schuurman H-J, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999 31 : 1024.
6. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 349 : 847.
7. Eisen HJ. Long-term cardiovascular risk in transplantation - insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006 21 (Suppl. 3 iii9.
8. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997 64 : 32.
9. Tomlanovich SJ, Vincenti F. Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol 2007 2 : 198.
10. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005 28 : 153.
11. Zuckermann A, Wang SS, Keogh A, et al. Everolimus with reduced-exposure cyclosporine in de novo heart transplant patients: 6-month results of a multicenter, randomized trial. Am J Transplant 2007 7 (Suppl. 2 443.
12. Arizon J, Lehmkuhl H, Livi U, et al. Everolimus with reduced-exposure cyclosporine versus MMF and standard-exposure cyclosporine in de novo cardiac transplant recipients: 12-month results from a multicenter, randomized trial. Am J Transplant 2008 8 (Suppl. 2 211.
13. Lehmkuhl H, Gerosa G, Arizon J, et al. Excellent efficacy with concentration-controlled everolimus in preventing biopsy-proven acute rejection following cardiac transplantation. Am J Transplant 2008 8 (Suppl. 2 573.
14. Nankivell BJ, Gruenewald SM, Allen R, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995 59 : 1683.
15. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990 9 : 587.
16. Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006 16 : 46.
17. Groetzner J, Kaczmarek I, Schulz U, et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009 87 : 726.
18. Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M. Calcineurin substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associatd with improved renal dysfunction in heart transplant patients. Clin Transplant 2007 21 : 305.
19. Gleissner CA, Doesch A, Ehlermann P, et al. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am J Transplant 2006 6 : 2750.
20. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: A review of clinical trial data, current usage, and future directions. Transplant Rev 2006 20 : 1.
21. Citterio F, Salvadori M, Stefoni S, et al. Upper everolimus blood levels with very low-dose cyclosporin in renal transplantation: 6-month results of the EVEREST study. Am J Transplant 2008 8 (Suppl. 2 1530 (abstract).
22. Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005 19 : 145.
23. Corbetta G, Salvadori M, Scolari MP, et al. Time-dependent analysis of influence of everolimus and CsA blood levels on the risk of acute rejection after renal transplantation. Transplantation 2008 86 (Suppl. 2 1648 (abstract).
24. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years a randomized clinical trial. Circulation 2004 110 : 2694.
25. Kobashigawa J, Miller L, Renlund D, et al. The Mycophenolate Mofetil Investigators. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998 66 : 507.